Amalgamated Bank Savara Inc Call Options Transaction History
Amalgamated Bank
- $13.6 Billion
- Q3 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding SVRA
# of Institutions
126Shares Held
160MCall Options Held
28.3KPut Options Held
24.9K-
Nea Management Company, LLC Timonium, MD24.5MShares$106 Million5.38% of portfolio
-
Bain Capital Life Sciences Investors, LLC Boston, MA17.6MShares$76.4 Million19.88% of portfolio
-
Vr Adviser, LLC New York, NY12.7MShares$55 Million6.78% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA12.4MShares$53.7 Million5.75% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA11.5MShares$49.7 Million1.71% of portfolio
About Savara Inc
- Ticker SVRA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 114,043,000
- Market Cap $495M
- Description
- Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.